



Council on Radionuclides and Radiopharmaceuticals, Inc.

3911 Campolindo Drive
Moraga, CA 94556-1551

E-mail:
david.sager@ge.com

David Sager,
Chairman

NOTICE TO THE NUCLEAR MEDICINE COMMUNITY

CORAR would like to update the nuclear medicine community on the molybdenum-99 (Mo-99) shortage created this week as a result of a technical issue that was experienced at the main reactor used by MDS Nordion for Mo-99 production.

We are pleased to be able to report that MDS Nordion has resolved their technical difficulties as of May 4, 2006 and their main reactor is now fully operational. However, as a result of the disruption in the supply of Mo-99, Bristol-Myers Squibb Medical Imaging's ability to produce technetium Tc99m generators will still be affected during the week of May 8, 2006. Since there are only two manufacturers of technetium Tc99m generators for the U.S. market, it is anticipated that there will be a temporary nationwide technetium shortage until MDS Nordion resumes full production and shipment of Mo-99.

Please know that the industry is diligently working to minimize the impact on physicians and their ability to provide care for their patients. The other U.S. technetium Tc99m generator manufacturer, Mallinckrodt, is boosting production to help alleviate the shortage but will be unable to fully meet market demand in the interim. Shipment of additional generators from Mallinckrodt will be allocated to help provide the best patient care possible under the circumstances.

Meanwhile industry members are exploring all options to increase the production and availability of Mo-99, including the sourcing of Mo-99 from other global suppliers. CORAR is committed to providing additional updates as more information becomes available.